Trust us

Home » About us

Our DNA

Icono misión

MISSION

Improving people's health through high-quality genetic and genomic services.

Icono visión

VISION

Have a leading position in the genetic diagnostic services market.

Icono valores

VALUES

Benefit for patients is the center of our activity.

International presence

In addition to Spain, NIMGenetics currently has offices in Portugal, Mexico and Brazil, where a highly qualified team of geneticists offers a comprehensive service to patients.

NIMGenetics also has partners in Europe, Latin America and the United States.

International presence

Our history

2008

NIMGENETICS ESTABLISHED

NIMGenetics was established by Dr Enrique Samper, Dr Juan Cruz Cigudosa and Dr Sara Álvarez as the main founding partners. In just one year, NIMGenetics positioned itself as a Spanish leading and pioneering company on Array CGH genome analysis, using genetic testing technology, which was approved by the Centre for the Development of Industrial Technology (CDTI).

2010

FIRST AWARDS

We were awarded the "Best Growth Project in SMEs" (IE Business School) and positioned ourselves as the only company in southern Europe certified by Agilent Technologies. In conjunction with TiGENIX, we won the INNPACTO- ASCIVAR Project to design a specific genetic diagnostic array for cell therapy.

2011

REDESIGN AND LAUNCH OF NEW SERVICES WITH QUALITY CERTIFICATIONS

We developed KaryoNIM® Postnatal, launched a new KaryoNIM® Prenatal test and obtained, for the first time, the Quality Certification from the Cytogenetics European Quality Association, as a certified genetic diagnostic laboratory using Array CGH methods.

2012

CONTINUED INNOVATION BY NIMGENETICS

We continue to develop new services targeting different neurological diseases and cancers: KaryoNIM® Autism 180K, KaryoNIM® Stem Cells, OncoNIM® Hereditary Cancer and OncoNIM® Cancer Diagnostics.

CREATION OF TRISONIM®, THE “PRENATAL REVOLUTION”

NIMGenetics revolutionized prenatal diagnosis by launching the first non-invasive prenatal screening test for pregnant women in Spain: TrisoNIM® (in collaboration with the Beijing Genomics Institute, BGI).

2013

AWARD FOR TRISONIM

TrisoNIM®, our non-invasive prenatal test, was recognised as one of the 100 Best Ideas 2012 for the health category, awarded by Actualidad Económica business magazine.

THE START OF OUR GLOBALISATION

BGI invited us to the International Congress on Non-Invasive Fetal Diagnosis in Prague, and Agilent Technologies to its California head office as expert advisers on In situ hybridisation technology.

2014

INTERNATIONAL EXPANSION

Always wanting to go further, NIMGenetics invested significant resources to reach new markets, such as Colombia, Chile, Peru, Paraguay, Uruguay and Portugal, as a spearhead for our international positioning and development.

WELCOME TO BRAZIL!

NIMGenetics Brazil became a reality, and we established a physical presence in one of the largest markets in the world.

2016

INNOVATIVE SME RECOGNITION 2016

The Innovative Companies Forum recognised us as the Innovative SME of 2016. A proud moment for the NIMGenetics team!

ISO 15189 FOR KARYONIM® POSTNATAL 60K AND 180K

NIMGenetics obtained the ISO 15189 accreditation for the study of array-CGH, being the first laboratory in Spain to demonstrate compliance with this standard, which accredits and demonstrates objectively and independently the commitment of a laboratory with quality and technical competence.

ACCELERATION IN THE OFFER OF SEQUENCING SERVICES 

NIMGenetics expanded its portfolio of services incorporating analysis in Trio, ExoNIM® Clinical and Directed, with more than 200 pre-designed panels. 

2017

APPOSITE CAPITAL INVIERTE 7 MILLONES DE EUROS EN NIMGENETICS

Apposite Capital is committed to the large NIM family, investing 7 million euros. Read the full note here.

OPENING OF NEW OFFICES IN ALCOBENDAS (MADRID)

We added new offices in Alcobendas (Madrid) to our headquarters in the Science Park of Madrid, where we have several laboratories and our logistics and sample registration center.

2018

INNOVATIVE SME ACCREDITATION

The Spanish Ministry of Economy and Competitiveness renewed our Innovative SME seal for our work in the field of Research, Development and Technological Innovation.

ISO 9001:2015 CERTIFICATION

Our management system was certified by Bureau Veritas, in accordance with ISO 9001:2015 Standard. The scope applies to providing diagnostic genetic testing services in pre-analytical, analytical and post-analytical stages for the specialities of genomics, non-invasive prenatal testing and molecular diagnostics.

WE ENHANCED OUR SEQUENCING CAPACITY 

Acquiring, the most powerful and safe sequencer on the world market, the NovaSeq™ 6000 from Illumina, gives us speed and reliability as a company specialized in personalized medicine. At that time, the only one in Spain dedicated to Medicine.

NIMSEQ® WAS BORN 

NIMGenetics expanded its portfolio of services by offering panels aimed at specific pathologies, both in the postnatal and prenatal areas. 

2019

NEW FOCUS: EARLY GYNECOLOGICAL CANCER DETECTION

NIMGenetics reached agreements for the distribution of GynTect (2019), which allowed us to fully enter the field of early gynecological cancer detection and prevention.

STILL COMMITTED TO QUALITY

NIMGenetics was accredited by ENAC for the ISO 15189 Standard in fetal aneuploidy screening (chromosomes 13, 18, 21, X and Y), and in maternal blood fetal sex determination through massive parallel sequencing (NGS), which corresponds to the TrisoNIM Basic and Basic Plus tests.

WE EXPAND PRENATAL DIAGNOSIS 

We developed the appropriate algorithms and technology for the incorporation of exon sequencing into prenatal diagnosis. 

ASSOCIATION OF SPANISH SCIENTISTS 

The Spanish Association of Scientists has recognized the work of NIMGenetics for its use of scientific knowledge in improving the health of patients with genetic diseases, as well as their life quality and that of their families.

2020

REVOLUTION IN PRENATAL DIAGNOSIS

We added TrisoNIM NeoSeq to our range of maternal blood fetal DNA tests, taking a qualitative step forward in non-invasive prenatal genetic testing by including dominant monogenic disorders.

 

INCORPORATION OF THE SUBSIDIARY OF NIM IN PORTUGAL 

After more than 5 years with a commercial presence in the Portuguese country, NIMGenetics opens an office in Lisbon which reinforce the work of the Portuguese team. 

RAPID REACTION TO COVID-19 

NIMGenetics supply the market with COVID-19 detection kits. As a leading biomedical company in genomic analysis and human genetic diagnosis, is our responsibility to make use of our knowledge and networks to facilitate the greatest number of tests to health agencies. 

2021

ISO 15189 certificate

NIMGenetics Brasil was recognized with the ISO 15189 certificate, which proves that the laboratory meets special quality and competence requirements, being the 5th laboratory in Brazil accredited to ISO 15189 - Clinical Laboratories.

NEW INVESTMENT BY APPOSITE CAPITAL 

Apposite Capital, a British private equity firm specialized in health, substantially increased its commitment to NIMGenetics by increasing by 6 million euros the investment already made in 2017. The procedure reaffirms our leading position in the field of clinical genetic diagnosis. Read the full press release here.

BRAZIL, ACCREDITED QUALITY 

NIMGenetics Brazil has obtained ISO 9001:2015 accreditation for the provision of genomic analysis and diagnosis services in the pre-analytical, analytical, and post-analytical stages in the field of human genetics. Likewise, the Brazil NIM team has achieved ISO 15189 accreditation, which demonstrates that the laboratory meets specific quality and competence requirements, being the fifth laboratory in Brazil accredited in this Standard.

GENONIM® ENTERS THE PORTFOLIO OF SERVICES

Genome Complete Sequencing (WGS) was incorporated into the NIMGenetics portfolio of services, offering an analysis aimed at maximizing its diagnostic profitability. 

EXONIM® EXPANDS ITS DIAGNOSTIC CAPACITY 

We incorporated into the extensive portfolio of ExoNIM®, in addition to the screening of CNVs, the analysis of the mitochondrial genome. 

2022

THE NIMGENETICS CATALOGUE GROWS 

Continuing with our goal of making available to medical specialists the best genetic diagnostic tools, two new products have been incorporated into the Reproductive line: FEMyTest®, an antigen test for the rapid detection of vaginitis, and ReceptIVFity®, the first non-invasive study of the vaginal microbiome for the analysis of the probability of reproductive success in IVF/ICSI treatments. Another of our novelties is Colotect®, a non-invasive test for the early detection of colorectal cancer (CRC) and precancerous lesions. 

ISO 9001:2015 FOR NIM PORTUGAL 

NIMGenetics Portugal achieves ISO 9001:2015 accreditation. The scope applies to the provision of genetic diagnostic analysis services in the pre-analytical, analytical and post-analytical stages for the specialties of genomics, non-invasive prenatal test, molecular diagnosis and NGS sequencing. 

AN EFFECTIVE ENVIRONMENTAL MANAGEMENT SYSTEM, ISO 14001 

Bureau Veritas accredits us in Spain and Portugal, at the level of environmental management, for having an efficient management of waste and complying with environmental legislation, as well as our own environmental policy.

DEVELOP YOUR TALENT IN THE NIMTEAM